BioImpacts. 2022;12: 261-290.
doi: 10.34172/bi.2022.23896
  Abstract View: 81
  PDF Download: 70


Recent advances in cancer immunotherapy: Modulation of tumor microenvironment by Toll-like receptor ligands

Leila Rostamizadeh 1 ORCID logo, Ommoleila Molavi 2,3* ORCID logo, Mohsen Rashid 1, Fatemeh Ramazani 1, Behzad Baradaran 4, Afsaneh Lavasanaifar 5, Raymond Lai 6

1 Department of Molecular Medicine, Faculty of Advanced Medical Science, Tabriz University of Medical Sciences, Tabriz, Iran
2 Biotechnology Research Centre, Tabriz University of Medical Sciences, Tabriz, Iran
3 Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
4 Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
5 Faculty of Pharmacy and Pharmaceutical Science, University of Alberta, Edmonton, Canada
6 Department of Laboratory Medicine & Pathology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Canada
*Corresponding Author: Corresponding author: Ommoleila Molavi, , Email: molaviazar@yahoo.com


Immunotherapy is considered a promising approach for cancer treatment. An important strategy for cancer immunotherapy is the use of cancer vaccines, which have been widely used for cancer treatment. Despite the great potential of cancer vaccines for cancer treatment, their therapeutic effects in clinical settings have been limited. The main reason behind the lack of significant therapeutic outcomes for cancer vaccines is believed to be the immunosuppressive tumor microenvironment (TME). The TME counteracts the therapeutic effects of immunotherapy and provides a favorable environment for tumor growth and progression. Therefore, overcoming the immunosuppressive TME can potentially augment the therapeutic effects of cancer immunotherapy in general and therapeutic cancer vaccines in particular. Among the strategies developed for overcoming immunosuppression in TME, the use of toll-like receptor (TLR) agonists has been suggested as a promising approach to reverse immunosuppression. In this paper, we will review the application of the four most widely studied TLR agonists including agonists of TLR3, 4, 7, and 9 in cancer immunotherapy.
Keywords: Immunotherapy, Cancer, TLRs, Microenvironment, Agonist, Vaccine
First Name
Last Name
Email Address
Security code

Abstract View: 82

Your browser does not support the canvas element.

PDF Download: 70

Your browser does not support the canvas element.

Submitted: 24 Jun 2021
Revision: 29 Nov 2021
Accepted: 04 Dec 2021
ePublished: 26 Mar 2022
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)